46 reports

  • Indication Name

The company is planning to initiate Phase II trial for food allergies such as peanut and grass allergy and in patients with multiple allergic disorders.

  • Asthma
  • Targeted Therapy
  • United States
  • Company
  • AstraZeneca PLC
  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H1 2018 (CONTD..8), H1 2018

It is under development for the treatment of asthma, eosinophilic esophagitis, bilateral nasal polyps, atopic dermatitis (adults-Japan and children-global) grass allergy, peanut allergy and food allergy.

  • Asthma
  • Pharmaceutical
  • Targeted Therapy
  • Therapy
  • AstraZeneca PLC
  • OMALIZUMAB - DRUG PROFILE

About ## percent of people who have food allergies are allergic to more than one food.

  • Targeted Therapy
  • Therapy
  • Canada
  • United States
  • Product Initiative
  • OMALIZUMAB - DRUG PROFILE

About ## percent of people who have food allergies are allergic to more than one food.

  • Pharmaceutical
  • Targeted Therapy
  • Japan
  • World
  • Product Initiative
  • RNAI GENE THERAPY FOR ASTHMA AND EOSINOPHILIC ESOPHAGITIS - DRUG PROFILE

Many studies suggest that food allergies are the main cause of EoE in children, including allergy to cow' s milk.

  • Digestive System Disorder
  • Targeted Therapy
  • Therapy
  • United States
  • Product Initiative
  • OMALIZUMAB - DRUG PROFILE

About ## percent of people who have food allergies are allergic to more than one food.

  • Pharmaceutical
  • Targeted Therapy
  • Japan
  • World
  • Product Initiative
  • OMALIZUMAB - DRUG PROFILE

About ## percent of people who have food allergies are allergic to more than one food.

  • Targeted Therapy
  • Therapy
  • Canada
  • United States
  • Product Initiative
  • OMALIZUMAB - DRUG PROFILE

About ## percent of people who have food allergies are allergic to more than one food.

  • Chronic Disease
  • Targeted Therapy
  • United States
  • Product Initiative
  • Regeneron Pharmaceuticals, Inc.

Selecta believes that this novel approach could be applied to other food allergies.

  • Monoclonal Antibody
  • Targeted Therapy
  • United States
  • Company
  • Selecta Biosciences, Inc.
  • OMALIZUMAB - DRUG PROFILE

About ## percent of people who have food allergies are allergic to more than one food.

  • Chronic Disease
  • Targeted Therapy
  • United States
  • Product Initiative
  • Regeneron Pharmaceuticals, Inc.
  • OMALIZUMAB - DRUG PROFILE

About ## percent of people who have food allergies are allergic to more than one food.

  • Monoclonal Antibody
  • Pharmaceutical
  • Respiratory Disease
  • Targeted Therapy
  • Regeneron Pharmaceuticals, Inc.

Aimmune discovers, develops and commercializes therapies related to food allergy.

  • Monoclonal Antibody
  • Pharmaceutical
  • Targeted Therapy
  • Therapy
  • Regeneron Pharmaceuticals, Inc.
  • 05/22/2017: NEW CANCER DRUG CAN PREVENT REACTIONS TO COMMON AIRBORNE ALLERGENS

THE PROMISING DATA FROM THIS PILOT STUDY COULD HAVE GREATER IMPLICATIONS FOR ADULTS WITH FOOD ALLERGIES.

  • Medical Biotechnology
  • Targeted Therapy
  • Therapy
  • United States
  • AbbVie Inc.

Its product candidates are being developed for the treatment of moderate-to-severe adult atopic dermatitis, food allergies and asthma, generalized pustular psoriasis and palmo-plantar pustular psoriasis and for the treatment of human autoimmune diseases.

  • Cancer
  • Targeted Therapy
  • United States
  • Company
  • TESARO, Inc.

The prominent features of this report are - ##.

  • Asthma
  • Clinical Trial
  • Pharmaceutical
  • Targeted Therapy
  • Novartis AG

Marcus Maurer, M. D., Professor of Dermatology and Allergy at Charité University in Berlin.

  • Clinical Trial
  • Pharmaceutical
  • Targeted Therapy
  • World
  • Product Initiative
  • IBRUTINIB - DRUG PROFILE

The promising data from this pilot study could have greater implications for adults with food allergies.

  • Leukemia
  • Targeted Therapy
  • Therapy
  • United States
  • Product Initiative

All other events were assessed as mild or moderate in severity except for a Grade ## food allergy that was considered unrelated to burosumab treatment.

  • Hospital
  • Targeted Therapy
  • Japan
  • United States
  • Kyowa Hakko Kirin Co., Ltd.
  • IBRUTINIB - DRUG PROFILE

The promising data from this pilot study could have greater implications for adults with food allergies.

  • Leukemia
  • Targeted Therapy
  • Therapy
  • United States
  • Product Initiative
  • 5. ALL THE TRIALS INCLUDED ARE UNIQUE TRIALS.

Bifidobacterium Infantis ## or Lactobacillus Salivarious UCC##, as Food Supplements for Maintenance of Remission in Ulcerative Colitis A One Year, Randomised, Double Blind, Placebo Controlled Trial of Probiotics.

  • Autoimmune Disease
  • Drug Development
  • Pharmaceutical
  • Targeted Therapy
  • World
  • Phase III - Trial Details

The promising data from this pilot study could have greater implications for adults with food allergies.

  • Dermatological Condition
  • Targeted Therapy
  • Therapy
  • United States
  • Product Initiative

The prominent features of this report are - ##.

  • Digestive System Disorder
  • Medical Biotechnology
  • Targeted Therapy
  • World
  • Product Initiative

BLOODY DIARRHEA BEING THE PROMINENT SYMPTOM OF UC, THE DISEASE CAN BE PRESENT WITHOUT BLEEDING, AND BE MISDIAGNOSED FOR CD, ACUTE INFECTIOUS COLITIS, IRRITABLE BOWEL SYNDROME (IBS), CELIAC DISEASE, OR FOOD ALLERGIES (MAYO CLINIC ARCHIVES, 2016; KARSTEN C ET AL., 2014).

  • Targeted Therapy
  • Market Size
  • EA Pharma Co., Ltd.
  • Pfizer Inc.
  • Remicade group
  • 7.1.3 DEALS BY MOLECULE TYPE, MECHANISM OF ACTION AND VALUE

Journal of Allergy and Clinical Immunology; ##(##): ## Lupus Foundation of America.

  • Targeted Therapy
  • AbbVie Inc.
  • Eli Lilly & Co.
  • Janssen Biotech, Inc.
  • Johnson & Johnson
  • IBRUTINIB - DRUG PROFILE

The promising data from this pilot study could have greater implications for adults with food allergies.

  • Cancer
  • Lymphoma
  • Targeted Therapy
  • United States
  • Product Initiative
  • VACCINE FOR CELIAC DISEASE - DRUG PROFILE

Food and Drug Administration (FDA).

  • Digestive System Disorder
  • Targeted Therapy
  • Therapy
  • United States
  • Product Initiative
  • PRU P 3 C1 ALLERGEN FOR PEACH ALLERGY - DRUG PROFILE

Consortium of Food Allergy Research (CoFAR).

  • Targeted Therapy
  • Vaccine
  • United States
  • Company
  • Company Operations
  • IMMUNOLOGY DRUGS MARKET, GLOBAL, TABLE OF ALL CLINICAL STAGE PIPELINE PRODUCTS, 2018, PART 14
  • IMMUNOLOGY DRUGS MARKET, GLOBAL, TABLE OF ALL CLINICAL STAGE PIPELINE PRODUCTS,

Food Allergy.

  • Healthcare
  • Monoclonal Antibody
  • Targeted Therapy
  • Company Financials
  • Forecast

The company is planning to initiate Phase II trial for food allergies such as peanut and grass allergy and in patients with multiple allergic disorders.

  • Dermatological Condition
  • Targeted Therapy
  • Therapy
  • United States
  • Product Initiative

ITI is also planning on initiating a Phase II study of JRC-LAMP-vax later 2013 and following that in 2014 with our first food allergy immunotherapy for peanut allergy, RA-LAMP-vax.

  • Targeted Therapy
  • United States
  • World
  • Company Operations
  • Immunomic Therapeutics, Inc.